Clinical Connection Home
  Welcome To
Clinical Connection
 
Be notified of new studies!
Hepatitis Clinical Trials, Diagnosis, and Treatment
Thank you for your interest in clinical trials for Hepatitis.

Please click "Search" to find Hepatitis clinical trials and medical research studies or read below for information on Hepatitis diagnosis and treatment.

If you receive too many study listings you may enter your zip code to find the locations closest to you.


Any Of These Words:
OR
All Of These Words
OR
This Exact Phrase:
AND
Zip Code:
Distance:
Search results will appear below.
Your search returned 3 studies:


Hepatitis C - Baltimore MD
Hepatitis C - Baltimore MD
Hepatitis B or C - Anaheim CA
Browse All Available Clinical Trials

Join Now to be Notified of New Clinical Trials

View Information and Clinical Trials for Other Conditions


Hepatitis

Hepatitis (plural hepatitides) implies injury to liver characterised by presence of inflammatory cells in the liver tissue. Etymologically from ancient Greek hepar (ηπαρ) or hepato- (ηπατο-) meaning 'liver' and suffix -itis denoting 'inflammation'. The condition can be self limiting, healing on its own or can progress to scarring of liver. Acute hepatitis is when it lasts less than 6 months and chronic hepatitis is when it persists longer. A group of viruses known as the hepatitis viruses cause most liver damages worldwide. Hepatitis can also be due to toxins (notably alcohol), other infections or from autoimmune process. It may run a subclinical course when the affected person may not feel ill. The patient becomes unwell and symptomatic when the disease impairs liver functions that include among other things, screening of harmful substances, regulation of blood composition and production of bile to help digestion.

Current Research

For current research articles click - here

Causes

Acute Hepatitis

  • Viral Hepatitis: Hepatitis A to E (more than 95% of viral cause), Herpes simplex, Cytomegalovirus, Epstein-Barr, yellow fever virus, adenoviruses.
  • Non viral infection: toxoplasma, Leptospira, Q fever, rocky mountain spotted fever
  • Alcohol
  • Toxins: Amanita toxin in mushrooms, Carbon tetrachloride, asafetida
  • Drugs: Paracetamol, amoxycillin, anti tuberculosis medicines, minocycline and many others (see longer list below).
  • Circulatory insufficiency
  • Pregnancy
  • Auto immune conditions e.g. SLE
  • Metabolic diseases e.g. Wilson's disease

Chronic Hepatitis

  • Viral Hepatitis: Hepatitis B with or without hepatitis D, Hepatitis C (Hepatitis A and E do not lead to chronic disease)
  • Autoimmune: Autoimmune hepatitis
  • Alcohol
  • Drugs: methyl-dopa, nitrofurantoin, isoniazide, ketoconazole
  • Non-alcoholic steatohepatitis
  • Heredity: Wilson's disease, alpha 1-antitrypsin deficiency
  • Primary biliary cirrhosis and primary sclerosing cholangitis occasionally mimic chronic hepatitis


Signs and Symptoms

Acute Hepatitis

Clinically the course of acute hepatitis varies widely from mild symptoms requiring no treatment to fulminant hepatic failure needing liver transplantation. Acute viral hepatitis are more likely to be asymptomatic in younger people. Symptomatic individuals may present after convalescent stage of 7 to 10 days, with the total illness lasting 2 to 6 weeks.

Initial features are of nonspecific flu-like symptoms, common to almost all acute viral infections and may include: malaise, muscle and joint aches, fever, feeling sick or vomiting, diarrhea and headache. More specific symptoms, which can be present in acute hepatitis from any cause are: profound loss of appetite, aversion of smoking among smokers, dark urine, yellowing of the eyes and skin i.e. jaundice and abdominal discomfort. Physical findings are usually minimal, apart from jaundice (33%) and tender hepatomegaly (10%). There can be occasional lymphadenopathy (5%) or splenomegaly (5%).

Chronic Hepatitis

Majority of patients will remain asymptomatic or mildly symptomatic, abnormal blood tests being the only manifestation. Features may be related to extent of liver damage or the cause of hepatitis. Many experience return of symptoms related to acute hepatitis. Jaundice can be a late feature and may indicate extensive damage. Other features include abdominal fullness from enlarged liver or spleen, low grade fever and fluid retention (ascites). Extensive damage and scarring of liver i.e. cirrhosis leads to weight loss, easy bruising and bleeding tendencies. Acne, abnormal menstruation, lung scarring, inflammation of the thyroid gland and kidneys may be present in women with autoimmune hepatitis.

Findings on clinical examination are usually those of cirrhosis or are related to aetiology.

Types of Hepatitis

Viral

Most cases of acute hepatitis are due to viral infections:
  • Hepatitis A
  • Hepatitis B
  • Hepatitis C
  • Hepatitis B with D
  • Hepatitis E
  • Hepatitis F (existence unknown)
  • Hepatitis G
  • In addition to the hepatitis viruses (please note that the hepatitis viruses are not all related). Other viruses can also cause hepatitis, including cytomegalovirus, Epstein-Barr virus, yellow fever, etc.

Hepatitis A

Hepatitis A or infectious jaundice is caused by a picornavirus. It is transmitted by the orofecal route, transmitted to humans through methods such as contaminated food. It causes an acute form of hepatitis and does not have a chronic stage. The patient's immune system makes antibodies against hepatitis A that confer immunity against future infection. People with hepatitis A are advised to rest, stay hydrated and avoid alcohol. A vaccine is available that will prevent infection from hepatitis A for life. Hepatitis A can be spread through personal contact, consumption of raw sea food or drinking contaminated water. This occurs primarily in third world countries. Strict personal hygiene and the avoidance of raw and unpeeled foods can help prevent an infection. Infected people excrete the hepatitis A virus with their faeces two weeks before and one week after the appearance of jaundice. The time between the infection and the start of the illness can run from 15 to 45 days, and approximately 15% of sufferers may experience relapsing symptoms from six months to a year following initial diagnosis.

Hepatitis B

Hepatitis B is caused by a hepadnavirus, which can cause both acute and chronic hepatitis. Chronic hepatitis develops in the 15% of patients who are unable to eliminate the virus after an initial infection. Identified methods of transmission include blood (blood transfusion, now rare), tattoos (both amateur and professionally done), sexually (through sexual intercourse or through contact with blood or bodily fluids), or in utero (from mother to her unborn child, as the virus can cross the placenta). However, in about half of cases the source of infection cannot be determined. Blood contact can occur by sharing syringes in intravenous drug use, shaving accessories such as razor blades, or touching wounds on infected persons. Needle-exchange programmes have been created in many countries as a form of prevention. In the United States, 95% of patients clear their infection and develop antibodies against hepatitis B virus. Five percent of patients do not clear the infection and develop chronic infection; only these people are at risk of long term complications of hepatitis B.

Patients with chronic hepatitis B have antibodies against hepatitis B, but these antibodies are not enough to clear the infection that establishes itself in the DNA of the affected liver cells. The continued production of virus combined with antibodies is a likely cause of immune complex disease seen in these patients. A vaccine is available that will prevent infection from hepatitis B for life. Hepatitis B infections result in 500,000 to 1,200,000 deaths per year worldwide due to the complications of chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Hepatitis B is endemic in a number of (mainly South-East Asian) countries, making cirrhosis and hepatocellular carcinoma big killers. There are six FDA-approved treatment options available for persons with a chronic hepatitis B infection: alpha-interferon, pegylated interferon adefovir, entecavir, telbivudine and lamivudine. About 45% of persons on treatment achieve a sustained response.

Hepatitis C

Hepatitis C (originally "non-A non-B hepatitis") is caused by a Flavivirus. It can be transmitted through contact with blood (including through sexual contact where the two parties' blood is mixed). Hepatitis C may lead to a chronic form of hepatitis, culminating in cirrhosis. It can remain asymptomatic for 10-20 years. Patients with hepatitis C are susceptible to severe hepatitis if they contract either hepatitis A or B, so all hepatitis C patients should be immunized against hepatitis A and hepatitis B if they are not already immune. The virus can cause cirrhosis of the liver. HCV viral levels can be reduced to undetectable levels by a combination of interferon and the antiviral drug ribavirin. The genotype of the virus determines the rate of response to this treatment regimen. Genotype 1 is more resistant to interferon therapy than other HCV genotypes.

Hepatitis D

Hepatitis D is considered a subviral satellite, as it can only propagate in the presence of the Hepatitis B virus.

Hepatitis E

Hepatitis E produces symptoms similar to hepatitis A, although it can take a fulminant course in some patients, particularly pregnant women; it is more prevalent in the Indian subcontinent.

Hepatitis F

Hepatitis F is a hypothetical virus linked to hepatitis. Several hepatitis F candidates emerged in the 1990s; none of these reports have been substantiated.

Hepatitis G

Another type of hepatitis, hepatitis G, has been identified, and is probably spread by blood and sexual contact. There is, however, doubt about whether it causes hepatitis, or is just associated with hepatitis, as it does not appear to be primarily replicated in the liver. Other viral infections can cause hepatitis (inflammation of the liver):
  • Mumps virus
  • Rubella virus
  • Cytomegalovirus
  • Epstein-Barr virus
  • Other herpes viruses

Alcoholic Hepatitis

Ethanol, mostly in alcoholic beverages, is a significant cause of hepatitis. Usually alcoholic hepatitis comes after a period of increased alcohol consumption. Alcoholic hepatitis is characterized by a variable constellation of symptoms, which may include feeling unwell, enlargement of the liver, development of fluid in the abdomen ascites, and modest elevation of liver blood tests. Alcoholic hepatitis can vary from mild with only liver test elevation to severe liver inflammation with development of jaundice, prolonged prothrombin time, and liver failure. Severe cases are characterized by either obtundation (dulled consciousness) or the combination of elevated bilirubin levels and prolonged prothrombin time; the mortality rate in both categories is 50% within 30 days of onset.

Alcoholic hepatitis is distinct from cirrhosis caused by long term alcohol consumption. Alcoholic hepatitis can occur in patients with chronic alcoholic liver disease and alcoholic cirrhosis. Alcoholic hepatitis by itself does not lead to cirrhosis, but cirrhosis is more common in patients with long term alcohol consumption. Patients who drink alcohol to excess are also more often than others found to have hepatitis C. The combination of hepatitis C and alcohol consumption accelerates the development of cirrhosis in Western countries.

Drug induced hepatitis

A large number of drugs can cause hepatitis. The anti-diabetic drug troglitazone was withdrawn in 2000 for causing hepatitis. Other drugs associated with hepatitis:
  • Allopurinol
  • Amitriptyline (antidepressant)
  • Amiodarone (antiarrhythmic)
  • Azathioprine[11][12]
  • Halothane (a specific type of anesthetic gas)
  • Hormonal contraceptives
  • Ibuprofen and indometacin (NSAIDs)
  • Isoniazid (INH), rifampicin, and pyrazinamide (tuberculosis-specific antibiotics)
  • Ketoconazole (antifungal)
  • Methyldopa (antihypertensive)
  • Minocycline (tetracycline antibiotic)
  • Nifedipine (antihypertensive)
  • Nitrofurantoin (antibiotic)
  • Phenytoin and valproic acid (antiepileptics)
  • Zidovudine (antiretroviral i.e. against AIDS)
  • Some herbs and nutritional supplements
The clinical course of drug-induced hepatitis is quite variable, depending on the drug and the patient's tendency to react to the drug. For example, halothane hepatitis can range from mild to fatal as can INH-induced hepatitis. Hormonal contraception can cause structural changes in the liver. Amiodarone hepatitis can be untreatable since the long half life of the drug (up to 60 days) means that there is no effective way to stop exposure to the drug. Statins can cause elevations of liver function blood tests normally without indicating an underlying hepatitis. Lastly, human variability is such that any drug can be a cause of hepatitis.

Other Toxins That Cause Hepatitis

Toxins and drugs can cause hepatitis:
  • Amatoxin-containing mushrooms, including the Death Cap (Amanita phalloides), the Destroying Angel (Amanita ocreata), and some species of Galerina. A portion of a single mushroom can be enough to be lethal (10 mg or less of α-amanitin).
  • White phosphorus, an industrial toxin.
  • Paracetamol (acetaminophen in the United States) can cause hepatitis when taken in an overdose. The severity of liver damage can be limited by prompt administration of acetylcysteine.
  • Carbon tetrachloride ("tetra", a dry cleaning agent), chloroform, and trichloroethylene, all chlorinated hydrocarbons, cause steatohepatitis (hepatitis with fatty liver).
  • Cylindrospermopsin, a toxin from the cyanobacterium Cylindrospermopsis raciborskii and other cyanobacteria.

Metabolic Disorders

Some metabolic disorders cause different forms of hepatitis. Hemochromatosis (due to iron accumulation) and Wilson's disease (copper accumulation) can cause liver inflammation and necrosis.

See below for non-alcoholic steatohepatitis (NASH), effectively a consequence of metabolic syndrome.

Obstructive

"Obstructive jaundice" is the term used to describe jaundice due to obstruction of the bile duct (by gallstones or external obstruction by cancer). If longstanding it leads to destruction and inflammation of liver tissue.

Autoimmune

Anomalous presentation of human leukocyte antigen (HLA) class II on the surface of hepatocytes—possibly due to genetic predisposition or acute liver infection—causes a cell-mediated immune response against the body's own liver, resulting in autoimmune hepatitis.

Autoimmune hepatitis has an incidence of 1-2 per 100,000 per year, and a prevalence of 15-20/100,000. As with most other autoimmune diseases, it affects women much more often than men (8:1). Liver enzymes are elevated, as is bilirubin. Autoimmune hepatitis can progress to cirrhosis. Treatment is with steroids and disease-modifying antirheumatic drugs (DMARDs).

The diagnosis of autoimmune hepatitis is best achieved with a combination of clinical and laboratory findings. A number of specific antibodies found in the blood (antinuclear antibody (ANA), smooth muscle antibody (SMA), Liver/kidney microsomal antibody (LKM-1) and anti-mitochondrial antibody (AMA)) are of use, as is finding an increased Immunoglobulin G level. However, the diagnosis of autoimmune hepatitis always requires a liver biopsy. In complex cases a scoring system can be used to help determine if a patient has autoimmune hepatitis, which combines clinical and laboratory features of a given case.

Four subtypes are recognised, but the clinical utility of distinguishing subtypes is limited.
  1. Positive ANA and SMA, raised immunoglobulin G (classic form, responds well to low dose steroids)
  2. Positive LKM-1 (typically female children and teenagers; disease can be severe)
  3. All antibodies negative, positive antibodies against soluble liver antigen (SLA)(now designated SLP/LP). This group behaves like group 1.
  4. No autoantibodies detected (~13%)

Alpha 1-Antitrypsin Deficiency

In severe cases of alpha 1-antitrypsin deficiency (A1AD), the accumulated protein in the endoplasmic reticulum causes liver cell damage and inflammation.

Nonalcoholic Steatohepatitis

Non-alcoholic steatohepatitis (NASH) is a type of hepatitis which resembles alcoholic hepatitis on liver biopsy (fat droplets, inflammatory cells, but usually no Mallory's hyaline) but occurs in patients who have no known history of alcohol abuse. NASH is more common in women and the most common cause is obesity or the metabolic syndrome. A related but less serious condition is called "fatty liver" (steatosis hepatis), which occurs in up to 80% of all clinically obese people. A liver biopsy for fatty liver shows fat droplets throughout the liver, but no signs of inflammation or Mallory's hyalin.

The diagnosis depends on history, physical exam, blood tests, radiological imaging and sometimes a liver biopsy. The initial evaluation to identify the presence of fatty infiltration of the liver is radiologic imaging including ultrasound, computed tomographic imaging, or magnetic resonance imaging. However, radiologic imaging cannot readily identify inflammation in the liver. Therefore, the differentiation between steatosis and NASH often requires a liver biopsy. It can also be difficult to distinguish NASH from alcoholic hepatitis when the patient has a history of alcohol consumption. Sometimes in such cases a trial of abstinence from alcohol along with follow -up blood tests and a repeat liver biopsy are required.

NASH is becoming recognized as the most important cause of liver disease second only to Hepatitis C in numbers of patients going on to cirrhosis.

Hepatitis Awareness

World Hepatitis Awareness Day is an annual event organised by several worldwide hepatitis advocacy groups to raise awareness of infectious hepatitis and demand action to curb the spread of the disease and treat people who are infected.


(adapted from Wikipedia, the free encyclopedia http://en.wikipedia.org/wiki/Hepatitis)





Findings From Current Research

Prevalence and Correlates of Hepatitis A Among Adult Drug Users: The Significance of Incarceration and Race/Ethnicity

Authors: Latimer WW, Moleko AG, Melnikov A, Mitchell M, Severtson SG, von Thomsen S, Graham C, Alama D, Floyd L.

Department of Mental Health, Johns Hopkins University Bloomberg School of Public Health, 624 N. Broadway Street, 850 Hampton House, Baltimore, MD 21205, United States.

This report examines associations between hepatitis A virus (HAV) infection prevalence and a history of incarceration in jail or a correctional facility among a population of drug users in Baltimore stratified by African American and white racial/ethnic status. The study sample consisted of 509 non-injection and injection drug users recruited from inner-city neighborhoods of the Baltimore metropolitan region. The baseline prevalence of HAV infection was 36.9% (N=188). One-fourth (25.5%) of the sample reported no lifetime history of incarceration, 44.6% reported incarceration in a local jail in their lifetime, and 29.9% reported incarceration in a correctional facility in their lifetime. In the multivariate logistic analysis, HAV infection prevalence was higher for whites (44.3%) [adjusted odds ratio (AOR)=2.3, 95% CI=1.5-3.5] when compared to African Americans (30.5%) adjusting for gender, age, and education. In the analysis stratified by race/ethnicity, as anticipated, jail incarceration and correctional facility incarceration were each independently associated with elevated HAV prevalence among white drug users. African American drug users with a high school diploma had significantly lower HAV infection prevalence when compared to African American drug users who did not graduate from high school. Heightened HAV prevalence among white drug users compared to African American drug users is noteworthy given the opposite association of HAV infection prevalence and these two racial/ethnic groups in the general population. Since millions of incarcerated drug users in the US return to society each year, the results suggest that incorporating systematic HAV screening, prevention, and treatment programs within correctional systems represents a vital yet underutilized strategy to reduce HAV transmission in society as a whole.

Journal: Vaccine. 2007 Aug 13
Adapted from PubMed; click here to access full journal article.




Customizing the Management of Chronic Hepatitis B Virus Infection

Authors: Gish RG, Perrillo RP, Jacobson IM.

Division of Hepatology and Complex GI, Physicians Foundation, California Pacific Medical Center, 2340 Clay Street, San Francisco, CA 94115, USA.

As of October 2006, 6 medications are approved in the United States for the management of chronic hepatitis B virus (HBV) infection: 2 formulations of interferon and 4 oral nucleos(t)ide analogues. For the treating practitioner, tailoring the pharmaceutical regimen according to patient features and clinical circumstances can be a challenge. First-line therapeutic regimens for the management of HBV infection include monotherapy with a U.S. Food and Drug Administration-approved agent that has potent on-treatment viral response and low rates of resistance; in the future, these regimens may include a combination of more than one nucleos(t)ide analogue or a combination of a nucleos(t)ide analogue and pegylated interferon. The oral nucleos(t)ide analogues are generally better tolerated than interferon; however, they can be expensive when administered for lengthy periods and can also lead to medication resistance. Lamivudine, the first approved nucleoside analogue for the treatment of HBV infection, has a very high resistance profile; in fact, lamivudine exposure increases viral resistance to other commercially available nucleos(t)ide analogues: entecavir, telbivudine, and adefovir. For these reasons, the 2007 American Association for the Study of Liver Diseases (AASLD) guidelines no longer recommend lamivudine as first-line therapy for the management of HBV infection. A satellite symposium conducted during the 57th Annual Meeting of the AASLD in Boston, Massachusetts, presented approaches to customizing the management of chronic HBV infection. The presentation highlighted recent findings suggesting that early, profound, and sustained viral suppression improves the probability of sustained virologic response and reduces the likelihood of nucleos(t)ide resistance.

Journal: Semin Liver Dis. 2007 Aug;27 Suppl 1:9-17.
Adapted from PubMed; click here to access full journal article.




Oral Aloe Vera-Induced Hepatitis (October)

Authors: Bottenberg MM, Wall GC, Harvey RL, Habib S.

Veterans Affairs Medical Center, Des Moines, IA; Assistant Professor of Pharmacy Practice, College of Pharmacy, Drake University, Des Moines.

OBJECTIVE: To report a case of possible oral aloe vera-induced hepatitis. CASE SUMMARY: A 73-year-old female was admitted to the hospital for acute hepatitis. Extensive laboratory testing did not reveal the cause of the patient's disease. She was asked multiple times whether she was taking any home medications, which she initially denied. It was only after an extensive medication history done by a clinical pharmacist that the patient admitted to using oral aloe vera capsules for constipation. Upon discontinuation of the oral aloe vera, liver markers of hepatotoxicity returned to normal levels. DISCUSSION: Herbal medications pose an increasing problem in patient safety, as the different types of these products and the number of patients who use them continue to grow. In the US, these products are not subject to the same regulatory scrutiny as prescription medications; thus, safety information can be difficult to obtain. In particular, hepatic toxicity due to herbal agents is poorly described in the medical literature. Aloe vera, often used topically for minor burns, can also be used orally as a laxative or an "anti-aging" agent. According to the Naranjo probability scale, the hepatotoxicity in this case was possibly related to ingestion of oral aloe vera. Additionally, using the Roussel Uclaf Causality Assessment Method for determining drug hepatotoxicity, the patient's symptoms were scored as probably caused by oral aloe vera. The more conservative designation was used in our report. CONCLUSIONS: With the widespread use of oral aloe vera and other herbal products, clinicians faced with a case of acute hepatitis that is not readily diagnosed should question patients about herbal use.

Journal: Ann Pharmacother. 2007 Aug 28;
Adapted from PubMed; click here to access full journal article.




Epstein-Barr Virus Hepatitis: Diagnostic Value of In Situ Hybridization, Polymerase Chain Reaction, and Immunohistochemistry on Liver Biopsy From Immunocompetent Patients

Authors: Suh N, Liapis H, Misdraji J, Brunt EM, Wang HL.

Department of Pathology and Immunology, Washington University School of Medicine ‡Department of Pathology, Saint Louis University School of Medicine, St Louis, MO †Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA.

Epstein-Barr virus (EBV) hepatitis is an uncommon, almost always self-limited disease in immunocompetent patients. Accurate diagnosis is imperative for appropriate clinical management. The aim of this study was to compare 3 available methods for EBV detection on routinely processed liver biopsies to determine their effectiveness in aiding the diagnosis. In 6 of the 8 cases of EBV hepatitis, EBV was detected by both polymerase chain reaction (PCR) for EBV DNA and in situ hybridization (ISH) for EBV early RNA (EBER). EBV was detected by PCR only in 1 case, and by ISH only in another. EBER-positive cells detected by ISH were typically few and individually distributed in the portal tracts and sinusoids. Immunohistochemical staining for EBV latent membrane proteins was negative in all 8 cases. Five cases of chronic hepatitis C used as negative controls were negative by all 3 detection methods for EBV. These data indicate that PCR and ISH are equally sensitive in detecting EBV in routinely processed liver biopsies. The ready implementation of ISH in pathology laboratories makes it a useful ancillary tool in confirming the diagnosis of EBV hepatitis in equivocal cases. However, EBER-positive cells can be sparse and easily overlooked. Immunohistochemistry for EBV latent membrane proteins apparently has no utility in the diagnosis of EBV hepatitis.

Journal: Am J Surg Pathol. 2007 Sep;31(9):1403-1409.
Adapted from PubMed; click here to access full journal article.




Hepatitis B Immunity in Children Vaccinated with Recombinant Hepatitis B Vaccine Beginning at Birth: A Follow-Up Study at 15 Years

Authors: Hammitt LL, Hennessy TW, Fiore AE, Zanis C, Hummel KB, Dunaway E, Bulkow L, McMahon BJ.

Arctic Investigations Program, Centers for Disease Control and Prevention, Anchorage, AK, United States; Alaska Native Tribal Health Consortium, Anchorage, AK, United States.

BACKGROUND: The duration of protection after hepatitis B vaccination of infants is unknown. We determined antibody to hepatitis B surface antigen (anti-HBs) and response to a booster dose 15 years after vaccination among Alaskan children born to hepatitis B surface antigen-negative mothers. These children had protective anti-HBs concentrations when tested after receiving a three-dose series of 2.5mug recombinant hepatitis B vaccine starting at birth. METHODS: Participants received 5mug of recombinant hepatitis B vaccine. Sera were collected at baseline, 10-14 days and 1 month after vaccination, and tested for antibody to hepatitis B core antigen (anti-HBc) and anti-HBs. An anamnestic response was defined as an anti-HBs increase within 15 days, from either undetectable to >/=10mIU/mL, or, if the baseline concentration was detectable, a 4-fold increase. RESULTS: None of 37 participants (mean age 14.6 years) were anti-HBc positive. An anamnestic response (GMC=254mIU/mL, range 16-2767mIU/mL) was observed in 18 (51%) of 35 participants who had sera collected within 15 days after the booster. CONCLUSIONS: In this small study, half of children who had received hepatitis B vaccine starting at birth did not have evidence of immune memory as measured by development of anamnestic responses to booster vaccination. Additional studies are needed to assess whether this indicates susceptibility to infection and whether persons vaccinated starting at birth may benefit from a hepatitis B vaccine booster to maintain long-term protection.

Journal: Vaccine. 2007 Jul 17
Adapted from PubMed; click here to access full journal article.




Update on Viral Hepatitis: 2006

Authors: Tan J, Lok AS.

Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan 48109-0362, USA.

PURPOSE OF REVIEW: This is a concise review of recent developments in the field of viral hepatitis, based on publications between December 2005 and November 2006. RECENT FINDINGS: Elevated hepatitis B virus DNA levels in patients in their 40s with perinatally acquired hepatitis B virus infection increases the risk for cirrhosis and hepatocellular carcinoma. Six approved therapies are available for chronic hepatitis B. Entecavir is a potent antiviral for nucleoside-naïve patients. For lamivudine resistant hepatitis B virus infection, adefovir should be added to lamivudine to reduce the risk of adefovir-resistant mutations; however, tenofovir may be a more promising alternative to adefovir. A shorter duration of treatment wth pegylated interferon and ribavirin is sufficient for genotype 2 hepatitis C infection but the benefits of extending treatment to 72 weeks for genotype 1 needs to be confirmed. Pegylated interferon monotherapy was shown to be effective in patients with hepatitis D and ribavirin provides no additional benefit. SUMMARY: New developments in the past year will help us fine tune the treatment of viral hepatitis. Even as new treatments are approved, the potential benefits of treatment should be weighed against the risk of drug-resistant mutations with long-term therapy.

Journal: Curr Opin Gastroenterol. 2007 May;23(3):263-7.
Adapted from PubMed; click here to access full journal article.




The Effect of Acetaminophen (Four Grams a Day for Three Consecutive Days) on Hepatic Tests in Alcoholic Patients--A Multicenter Randomized Study

Authors: Kuffner EK, Green JL, Bogdan GM, Knox PC, Palmer RB, Heard K, Slattery JT, Dart RC.

Rocky Mountain Poison & Drug Center, Denver Health, Denver, CO, USA. ekuffner@mccus.jnj.com

BACKGROUND: Hepatic failure has been associated with reported therapeutic use of acetaminophen by alcoholic patients. The highest risk period for alcoholic patients is immediately after discontinuation of alcohol intake. This period exhibits the largest increase in CYP2E1 induction and lowest glutathione levels. Our hypothesis was that common liver tests would be unaffected by administration of the maximum recommended daily dosage of acetaminophen for 3 consecutive days to newly-abstinent alcoholic subjects. METHODS: Adult alcoholic subjects entering two alcohol detoxification centers were enrolled in a prospective double-blind, randomized, placebo-controlled trial. Subjects were randomized to acetaminophen, 4 g/day, or placebo for 3 consecutive days. The study had 95% probability of detecting a 15 IU/L difference in serum ALT. RESULTS: A total of 443 subjects were enrolled: 308 (258 completed) received acetaminophen and 135 subjects (114 completed) received placebo. Study groups did not differ in demographics, alcohol consumption, nutritional status or baseline laboratory assessments. The peak mean ALT activity was 57 +/- 45 IU/L and 55 +/- 48 IU/L in the acetaminophen and placebo groups, respectively. Subgroup analyses for subjects presenting with an elevated ALT, subjects fulfilling a diagnosis of alcoholic hepatitis and subjects attaining a peak ALT greater than 200 IU/L showed no statistical difference between the acetaminophen and control groups. The one participant developing an increased international normalized ratio was in the placebo group. CONCLUSION: Alcoholic patients treated with the maximum recommended daily dose of acetaminophen for 3 consecutive days did not develop increases in serum transaminase or other measures of liver injury. Treatment of pain or fever for 3 days with acetaminophen appears safe in newly-abstinent alcoholic patients, such as those presenting for acute medical care.

Journal: BMC Med. 2007 May 30;5:13.
Adapted from PubMed; click here to access full journal article.




Join Now - Become a free member and get notified about studies in your area when they become available.

Browse Our Current Studies - Look over all of our current studies being conducted throughout the United States.

View Information and Clinical Trials for Other Conditions - Access all of our health-related content.
Depression - Virginia Beach VA
in Virginia Beach, VA


Hypertension (High Blood Pressure) - Sacramento CA
in Carmichael, CA


Migraine - Virginia Beach VA
in Virginia Beach, VA


Bipolar Depression - Norristown PA
in Norristown, PA


Depression - Norristown PA
in Norristown, PA


Adolescent Depression - Virginia Beach VA
in Virginia Beach, VA


Major Depression - New York NY
in New York, NY


Bipolar Depression - New York NY
in New York, NY


Generalized Anxiety Disorder - New York NY
in New York, NY


Are You Ready to Quit Smoking? - Menlo Park CA
in Menlo Park, CA


Psoriasis - Baltimore MD
in Baltimore, MD


Migraine- Virginia Beach VA
in Virginia Beach, VA


ADHD in Children and Adolescents - Chapel Hill NC
in Chapel Hill, NC


Eczema (Atopic Dermatitis) - NATIONWIDE
in NATIONWIDE,


Osteoarthritis - Virginia Beach VA
in Virginia Beach, VA


Genital Warts - NATIONWIDE
in NATIONWIDE,


Diabetic Neuropathy - DeLand FL
in DeLand, FL


Osteoarthritis of the Knee - NATIONWIDE
in NATIONWIDE,


Healthy Volunteers (Sleep Disorders) - DeLand FL
in DeLand, FL


ADHD in Children and Adolescents - NATIONWIDE
in NATIONWIDE,


 


© 1998-2008 Clinical Trials Home | Links | Terms And Conditions | Sitemap | Suggestion/Feedback
All trademarks are property of their legal owners. | All Rights Reserved

ClinicalConnection.com is a resource that provides individuals with information regarding clinical trials that are being conducted nationwide.
ClinicalConnection.com does not conduct these clinical trials nor endorse them. Please consult your doctor or physician before participating.